Open AccessUse of Aspirin in normalization of recombinant human erythropoietin-mediated hyper-reactivity of platelets in rats
Author(s) -
Hitesh Soni,
Amit Vekaria,
Akshyaya Rath,
Sateesh Belemkar,
Mukul Jain
Publication year - 2014
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/0253-7613.132187
Subject(s) - medicine , aspirin , erythropoietin , platelet , anemia , bleeding time , platelet activation , endocrinology , gastroenterology , pharmacology , platelet aggregation
The cytokine erythropoietin is the primary stimulator of erythropoiesis and recombinant human erythropoietin (rHuEPO), which is widely used in the treatment of anemia associated with advanced chronic kidney disease (CKD). Adverse cardiovascular outcomes have been observed during clinical trials of anemia correction with rHuEPO in CKD patients. We investigated the effects of short-term, high-dose treatment with rHuEPO on platelet reactivity and effects of aspirin on platelet reactivity in healthy rats.